活血祛湿方对纯化高脂饲料诱导大鼠非酒精性脂肪性肝炎模型的影响

发布时间：2018-05-15 02:37

本文选题：活血祛湿方 + 纯化高脂饲料　；参考：《中国实验方剂学杂志》2016年07期

【摘要】：目的:观察不同剂量活血祛湿方对纯化高脂饲料诱导的大鼠非酒精性脂肪性肝炎(NASH)模型的治疗作用,探讨活血祛湿方治疗NASH的作用机制。方法:纯化高脂饲料制备Wistar大鼠NASH模型8周,随机分为罗格列酮组(3 mg·kg-1·d-1),活血祛湿方组高、中、低剂量组(32,16,8 g·kg-1·d-1)及模型组,另设正常组。第9周开始ig给药;正常组及模型组均给予等量生理盐水ig。药物干预4周后行血清生化指标,懫用比色法检测血清丙氨酸氨基转移酶(ALT),天门冬氨酸氨基转移酶(AST),甘油三酯(TG),总胆固醇(TC)及高密度脂蛋白胆固醇(HDL-C)含量,放射免疫法检测血清空腹血糖(FBG),空腹胰岛素(FINS),酶联免疫吸附法(ELISA)法检测炎症因子肿瘤坏死因子-α(TNF-α),白细胞介素-10(IL-10)及IL-6;检测肝组织中超氧化物岐化酶(SOD)活性及丙二醛(MDA)含量;苏木素-伊红(HE)染色观察肝脏组织病理学变化;卵白素-生物素-酶复合物染色(ABC)法检测肝脏组织细胞色素P4502E1(CYP2E1)含量及分布;逆转录-聚合酶链式反应(RT-PCR)法检测过氧化物酶体增殖剂活化受体α(PPARα)mRNA表达。结果:与正常组比较,模型组大鼠血清ALT,AST,TG,TC水平及FBG,FINS,TNF-α及IL-6含量明显升高,HDL-C,IL-10含量明显降低,肝组织SOD活性明显降低,MDA及CYP2E1含量明显升高,肝脏PPARαmRNA表达明显降低,均具有明显的统计学差异(P0.05);与模型组比较,活血祛湿方各剂量组均能够改善大鼠NASH模型各项血清生化指标,降低FBG,FINS水平,明显提高肝脏PPARαmRNA表达,明显增加肝脏中SOD活性及IL-10的含量,明显减少肝脏MDA,CYP2E1,TNF-α及IL-6含量,与模型组比较,差异有统计学意义(P0.05)。病理结果显示,肝脏组织病理损伤明显改善。结论:活血祛湿方能够有效多途径治疗NASH,改善胰岛素抵抗,减少脂质过氧化反应,抑制炎症反应可能是其治疗NASH的机制。
[Abstract]:Objective: to observe the therapeutic effect of different doses of Huoxue Qushi recipe on the model of non-alcoholic fatty hepatitis induced by purified high-fat diet in rats, and to explore the mechanism of Huoxue Qushi prescription in treating NASH. Methods: the NASH model of Wistar rats was prepared by purification of high fat diet for 8 weeks. The rats were randomly divided into rosiglitazone group (3 mg kg-1 d -1), high, middle and low dosage groups with high, middle and low doses of RPG 3 mg kg-1 d-1) and model group, and normal group. Normal group and model group were given the same amount of saline. Serum biochemical indexes were measured by colorimetry after 4 weeks of drug intervention. The contents of serum alanine aminotransferase (alt), aspartate aminotransferase (AST), triglyceride (TGN), total cholesterol (TC) and high density lipoprotein cholesterol (HDL-C) were determined by colorimetric method. Serum fasting blood glucose (FBGG), fasting insulin (FINSN), serum inflammatory factor tumor necrosis factor- 伪 (TNF- 伪), interleukin-10 (IL-10) and interleukin-6 (IL-6) were detected by radioimmunoassay, and the activity of superoxide dismutase (SOD) and the content of malondialdehyde (MDA) in liver tissue were detected by radioimmunoassay (RIA) and enzyme linked immunosorbent assay (Elisa). The histopathological changes of liver were observed by hematoxylin-eosin (HEH) staining, and the content and distribution of cytochrome P4502E1 (CYP2E1) were detected by ABC staining. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the expression of peroxisome proliferator activated receptor 伪 -PPAR 伪 -PPAR 伪 mRNA. Results: compared with the normal group, the level of serum alt ASTGN TC, the content of FBGG FINSN TNF- 伪 and the content of IL-6 in the model group were significantly higher than those in the normal group. The activity of SOD in the liver decreased significantly, and the content of CYP2E1 and PPAR 伪 mRNA in the liver decreased significantly. Compared with the model group, each dose group of Huoxue Qushi recipe could improve the serum biochemical indexes, decrease the level of fins and increase the expression of PPAR 伪 mRNA in the liver. The activity of SOD and the content of IL-10 in the liver were significantly increased, and the contents of TNF- 伪 and IL-6 in the liver of MDA-CYP2E1 were significantly decreased compared with the model group (P 0.05). The pathological results showed that the pathological injury of liver tissue was obviously improved. Conclusion: Huoxue Qishi prescription can effectively treat NASH, improve insulin resistance, reduce lipid peroxidation and inhibit inflammatory reaction, which may be the mechanism of its treatment of NASH.
【作者单位】：辽宁中医药大学;辽宁中医药大学附属医院;
【基金】：辽宁省自然科学基金项目(201102142)
【分类号】：R285.5;R-332

【相似文献】